Sirnaomics Secures HKD 138 Million Strategic Investment from Bloomage Biotech for RNAi Therapeutics Development
Key Insights
Bloomage Biotech (search) invested HKD 138 million in Sirnaomics at HKD 12 per share, acquiring a 9.44% stake to accelerate development of RNAi therapeutics in aesthetics, longevity, and regenerative medicine.
The strategic partnership combines Sirnaomics' proprietary PNP (search) and GalAhead™ delivery platforms with Bloomage's hyaluronic acid expertise and commercial capabilities in Greater China.
The collaboration will focus on advancing Sirnaomics' STP705 targeted fat reduction program and developing next-generation precision-delivery solutions for aesthetic applications.
Sirnaomics Ltd., a leading biopharmaceutical company specializing in RNAi therapeutics, announced a strategic equity investment of approximately HKD 138 million from Bloomage Biotech (search) through its wholly-owned subsidiary, Bloomage Biotechnology (Hong Kong) Limited. The investment, priced at HKD 12 per share, will give Bloomage Biotech approximately 9.44% of Sirnaomics' total issued share capital upon completion.
Strategic Partnership for Aesthetic and Regenerative Medicine
The investment is specifically designed to accelerate the development and commercialization of Sirnaomics' programs in aesthetics, longevity intervention, and regenerative medicine. Bloomage Biotech (search) will contribute substantial resources, including clinical development expertise and commercial capabilities in the Greater China region and globally, with particular focus on the STP705 targeted fat reduction program and other siRNA-based aesthetic pipeline assets.
The collaboration leverages complementary strengths from both companies. Bloomage Biotech (search) brings extensive expertise in hyaluronic acid biomanufacturing, glycobiology, and cell biology, which will be integrated with Sirnaomics' proprietary RNAi delivery platforms, PNP (search) (Polypeptide Nanoparticle) and GalAhead™, to co-develop next-generation precision-delivery solutions.
Technology Integration and Platform Development
The strategic alignment enables Sirnaomics to efficiently allocate its internal resources toward advancing other pipeline programs in oncology and autoimmune diseases, while leveraging Bloomage's strengths to maximize the value of its aesthetics portfolio. The collaboration will explore broader opportunities by combining Sirnaomics' proprietary delivery platforms with Bloomage Biotech (search)'s extensive research in hyaluronic acid and biologics.
This partnership positions both companies to capitalize on the expanding RNAi therapeutics market, particularly in high-growth sectors such as aesthetics and regenerative medicine. The integration of advanced delivery systems with established biomanufacturing expertise represents a significant step forward in developing commercially viable RNAi-based treatments for non-oncology applications.
Market Positioning and Future Development
The joint venture's focus on the Greater China market aligns with projected growth in RNAi adoption in the region. By combining financial resources, technological capabilities, and commercial expertise, the partnership aims to accelerate the development timeline for precision-delivery products that could redefine standards in cosmeceutical and regenerative medicine applications.
Sirnaomics maintains a robust pipeline of over 10 programs and is recognized as the first clinical-stage RNAi therapeutics company with a strong presence in both Asia and the United States. The company's proprietary delivery technologies are pioneering the development of RNAi therapies for tissues beyond the liver, expanding the therapeutic potential of RNA interference technology across multiple disease areas and aesthetic applications.